IRADIMED CORP Cash Flow Statement
IRMD / Health Care|13 years of annual SEC 10-K data (FY2013-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 13 fiscal years. All figures from audited SEC 10-K filings.
IRADIMED CORP generated $25M in operating cash flow and $17M in free cash flow in FY2025. Free cash flow margin was 20.5% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 5.29 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.1%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $22.5M | $19.2M | $17.2M | $9.3M | $9.3M | $1.4M | $9.6M | $6.3M | $499.8K | $7.2M | $7.5M | $1.9M | $1.9M |
| Depreciation & Amortization | $1.2M | $818.0K | $765.2K | $1.4M | $1.4M | $1.3M | $1.2M | $1.1M | $1.3M | $955.8K | $807.3K | $139.0K | $139.0K |
| Operating Cash Flow | $24.9M | $25.6M | $13.5M | $11.3M | $11.3M | $5.8M | $10.2M | $7.4M | $3.4M | $9.4M | $7.6M | $1.5M | $1.5M |
| Capital Expenditures | $7.8M | $8.0M | $7.4M | $482.3K | $482.3K | $443.0K | $368.3K | $228.3K | $775.6K | $780.8K | $298.7K | $163.2K | $163.2K |
| Free Cash Flow | $17.2M | $17.6M | $6.0M | $10.8M | $10.8M | $5.4M | $9.9M | $7.1M | $2.6M | $8.6M | $7.4M | $1.3M | $1.3M |
| Share Buybacks | - | - | - | - | - | - | - | - | $1.8M | $10.0M | - | - | - |
| Dividends Paid | $15.0M | $13.7M | $13.2M | $12.6M | - | - | - | - | - | - | - | - | - |
| FCF Margin | 20.5% | 24.1% | 9.2% | 25.8% | 25.8% | 16.9% | 25.6% | 23.5% | 11.4% | 26.5% | 23.3% | 11.6% | 11.6% |